effects of ursodeoxycholic acid on neonatal indirect jundice

effects of ursodeoxycholic acid (UDCA) on neonatal indirect hyperbilirubinemia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171124037615N1

Enrollment

200

Registered

2018-01-08

Start date

2017-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Indirect hyperbilirubinemia. Other disorders of bilirubin metabolism

Interventions

Intervention group: ursodeoxycholic acid.

Treatment - Drugs

Intervention group: ursodeoxycholic acid

Eligibility

Sex/Gender

All

Age

3 Days to 5 Days

Inclusion criteria

Inclusion criteria: Individuals with indirect pathologic Hyperbilirubinemia A 3-5 day baby with a birth weight of 2.5 to 4 kg fed on breast milk- Tobol bilirubin levels between 12 to 20 mg / dl and direct bilirubin levels <2 mg / dl

Exclusion criteria

Exclusion criteria: Having any of the liver, metabolic, sepsis diseases The use of any other drug that has an effect on the level of bilirubin

Design outcomes

Primary

Measure	Time frame
Total bilirubin. Timepoint: Every 24 hours. Method of measurement: ??Auto analyzer.	—

Secondary

Measure	Time frame
Direct bilirubin. Timepoint: every 24 hour. Method of measurement: Autoanalyzer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdiye soleimani far

Zabol University of Medical Sciences

msoleimanyfar@gmail.com+98 54 3225 4700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026